GeneHealth - Your precision medicine

Progressive Myoclonus Epilepsy

Disease Details

Family Health Simplified

Buy Membership

Description: Progressive myoclonus epilepsy is a group of rare, inherited neurodegenerative disorders characterized by myoclonic seizures, progressive neurological decline, and cognitive impairment.
Type: Progressive myoclonus epilepsy (PME) is a type of genetic disorder characterized by myoclonic seizures, epileptic seizures, and progressive neurological decline. The type of genetic transmission of PME can be autosomal recessive, autosomal dominant, or X-linked, depending on the specific subtype of the disease.
Signs And Symptoms: The most common symptom of PME is myoclonus. The myoclonus can be fragmented or multifocal and can be triggered by posture, actions, and external stimuli such as light, sound, and touch. The type of myoclonus differs between the types of PME. Other symptoms of PME include generalized, tonic clonic, tonic, and atypical absence seizures. In Lafora's disease the seizures are occipital and the person experiences transient blindness as well as visual hallucinations. The person may also have atypical absences and atonic and complex partial seizures. In Myoclonus epilepsy with ragged-red fibers (MERRF) the person experiences generalized epilepsy along with myoclonus, weakness, and dementia.As PME progresses neurological ability decreases and can lead to myopathy, neuropathy, cognitive decline, cerebellar ataxia, and dementia. The different symptoms in each of the PME and between individuals makes diagnosis difficult. Therefore, diagnosis of PME is dependent on failure to respond to antiepileptic drugs and therapy but diagnosis of specific PME depends on genetic testing, EEG (electroencephalography), enzyme measurements and more.
Prognosis: The prognosis of PME is ultimately dependent on the type of PME. In Lafora body disease the neurological deterioration progresses until resulting in a vegetative state and death within 10 years of diagnosis. Due to research and advances in antiepileptic medication, individuals with ULD can live up to 60 years of age. Nevertheless, severe myoclonus can lead to injury by falling and becoming reliant on a wheelchair.
Onset: Progressive myoclonus epilepsy (PME) typically has an onset during childhood or adolescence, generally between the ages of 6 and 15.
Prevalence: The prevalence of progressive myoclonus epilepsy (PME) varies depending on the specific subtype, but it is generally considered rare. Exact prevalence rates can be difficult to determine, but PME is estimated to occur in roughly 1 to 4 per 100,000 individuals.
Epidemiology: PME accounts for less than 1% of epilepsy cases at specialist centres. The incidence and prevalence of PME is unknown, but there are considerable geography and ethnic variations amongst the specific genetic disorders. One cause, Unverricht Lundborg Disease, has an incidence of at least 1:20,000 in Finland.
Intractability: Progressive myoclonus epilepsy (PME) is often considered intractable because it is typically difficult to control with standard antiepileptic treatments. The condition involves a combination of myoclonic seizures, generalized tonic-clonic seizures, and progressive neurological decline, which complicates management and leads to a poor prognosis in many cases.
Disease Severity: Progressive myoclonus epilepsy (PME) is a group of rare genetic disorders that affect the central nervous system. Here are the key points:

1. **Disease Severity**: PME typically presents with a combination of severe myoclonus (involuntary muscle jerks), epilepsy (recurrent seizures), and other neurological symptoms. The disease is progressive, often leading to significant disability over time. Severity can vary widely depending on the specific type of PME and the progression of symptoms.

2. **Nan**: The context of "nan" is unclear in medical terms. If it refers to a lab measurement, it might be a value not applicable or not a number. Please clarify the term for a more accurate response.
Healthcare Professionals: Disease Ontology ID - DOID:891
Pathophysiology: Progressive myoclonus epilepsy (PME) is a group of rare genetic disorders characterized by myoclonic seizures, other types of seizures, and progressive neurological decline. The pathophysiology of PME involves mutations in specific genes that affect neuronal function, leading to abnormal neuronal excitability and disturbed brain signaling.

These genetic mutations often impair the function of proteins critical for maintaining normal cellular processes, such as lysosome function, ion channel regulation, or mitochondrial activity. For example, mutations in the EPM1 gene (encoding cystatin B) or in the EPM2A gene (encoding laforin) disrupt cellular homeostasis and contribute to the accumulation of abnormal substances within neurons, such as glycogen or amyloid precursor proteins. The result is progressive neuronal death, brain tissue degeneration, and consequently, the worsening of motor and cognitive functions seen in affected individuals.
Carrier Status: Progressive myoclonus epilepsy (PME) encompasses a group of rare, inherited disorders. Carrier status is often linked to specific mutations in genes such as CSTB, PRICKLE1, and others. Carrier individuals typically do not exhibit symptoms but can pass the mutated gene to their offspring. If you need more detailed information about a specific type of PME or genetic testing, please provide additional context.
Mechanism: Progressive myoclonus epilepsy (PME) is a group of genetic disorders characterized by myoclonus (brief, involuntary twitching of muscles), epilepsy (recurrent seizures), and neurological decline. The underlying mechanisms and molecular mechanisms of PME vary depending on the specific subtype of the disorder.

**Mechanism:**
1. **Genetic Mutations:** PME is often caused by mutations in specific genes that affect the function of proteins critical for neuronal health and function.
2. **Neuronal Dysfunction:** These genetic mutations typically result in defective proteins that disrupt normal neuronal activities, leading to neuronal degeneration and loss of function.
3. **Accumulation of Toxic Substances:** In some forms of PME, there is an accumulation of toxic substances within neurons, which causes cellular damage and leads to the symptoms of the disease.

**Molecular Mechanisms:**
1. **CLN Genes:** Mutations in CLN genes (such as CLN1, CLN2, etc.) are associated with a subgroup known as neuronal ceroid lipofuscinoses (NCL). These genes encode proteins involved in lysosomal function, and their dysfunction leads to the accumulation of lipofuscin inside neurons.
2. **PRICKLE1 Gene:** Mutations in the PRICKLE1 gene can lead to defective signaling pathways that are essential for normal neuronal function.
3. **Lafora Disease:** Caused by mutations in the EPM2A gene, which encodes laforin, and NHLRC1 gene, encoding malin. Both proteins are involved in glycogen metabolism; their dysfunction results in the formation of Lafora bodies (abnormal glycogen aggregates) within neurons.
4. **GOSR2 Gene:** This gene encodes a protein involved in vesicle transport. Mutations disrupt normal protein trafficking within neurons.
5. **SCARB2 Gene:** Mutations in SCARB2, associated with action myoclonus-renal failure syndrome (AMRF), affect lysosomal membrane proteins involved in lysosomal biogenesis and function.

Overall, the molecular mechanisms involve disruptions in lysosomal function, glycogen metabolism, and protein trafficking, leading to neuronal dysfunction and degeneration in PME.
Treatment: Progressive Myoclonus Epilepsy (PME) is a group of rare genetic disorders characterized by myoclonus (involuntary muscle jerks), epilepsy, and often other neurological symptoms. Treatment focuses on managing symptoms, as there is no cure.

1. **Antiepileptic Drugs (AEDs)**: Medications like valproate, levetiracetam, and clonazepam are commonly used to control seizures and myoclonus.

2. **Physical Therapy**: Helps improve motor skills and coordination.

3. **Speech Therapy**: Assists with communication difficulties if present.

4. **Gene Therapy and Enzyme Replacement**: These are experimental areas that may offer future solutions.

Each patient may require a tailored approach depending on the specific subtype and severity of PME. Regular follow-ups with a neurologist specializing in epilepsy are essential.
Compassionate Use Treatment: For Progressive Myoclonus Epilepsy (PME), compassionate use treatments and off-label or experimental treatments may be considered when standard therapies are not effective. Some of the approaches include:

1. **Antiepileptic Drugs (AEDs)**: While some AEDs are commonly prescribed, off-label use of certain AEDs such as Levetiracetam and Zonisamide may be tried.

2. **Cannabidiol (CBD)**: There's emerging evidence suggesting that CBD might benefit patients with treatment-resistant epilepsy, including some forms of PME.

3. **N-Acetylcysteine (NAC)**: This antioxidant has been used experimentally to reduce oxidative stress in neuronal cells, potentially offering symptom relief in some PME patients.

4. **Gene Therapy**: Experimental gene therapies are being researched, particularly for specific genetic mutations associated with PME, though this is still in investigational stages.

5. **Deep Brain Stimulation (DBS)**: This is a neurosurgical treatment that has been used on an experimental basis to reduce seizures and myoclonus in some patients.

6. **Stem Cell Therapy**: Experimental stem cell treatments are currently being explored for their potential to replace or repair damaged neural tissues in PME.

It is crucial to consult a neurologist or a specialized healthcare provider to discuss the risks and benefits of these treatments, and to explore eligibility for clinical trials or compassionate use programs.
Lifestyle Recommendations: For individuals diagnosed with progressive myoclonus epilepsy (PME), here are some lifestyle recommendations to consider:

1. **Medication Adherence**: Regularly take anti-seizure medications as prescribed by a healthcare provider to help control seizures.

2. **Routine Medical Check-Ups**: Frequent visits to healthcare professionals for monitoring the progression of the disease and adjusting treatment as needed.

3. **Seizure Triggers**: Identify and avoid potential seizure triggers, such as stress, lack of sleep, and certain visual or auditory stimuli.

4. **Healthy Diet**: Maintain a balanced diet to support overall health. Some people may benefit from special diets like the ketogenic diet, but this should be done under medical supervision.

5. **Regular Exercise**: Engage in regular, moderate exercise to maintain physical health, but avoid activities that could increase the risk of injury during a seizure.

6. **Mental Health Support**: Seek support for associated psychological challenges, such as anxiety and depression, which can accompany PME.

7. **Safety Precautions**: Implement safety measures in the home to prevent injuries during seizures, such as padding sharp corners and using a shower chair.

8. **Social Support**: Stay connected with family and friends for emotional support, and consider joining support groups for individuals with epilepsy.

9. **Avoid Alcohol and Drugs**: Refrain from consuming alcohol and recreational drugs, as they can exacerbate seizures.

10. **Rest**: Ensure adequate rest and manage sleep disorders, as fatigue can increase seizure frequency.

These recommendations should be personalized in consultation with a healthcare provider to best meet individual needs.
Medication: Medications used to manage Progressive Myoclonus Epilepsy (PME) often include antiepileptic drugs (AEDs) such as valproic acid, clonazepam, and levetiracetam. The choice of medication depends on the specific symptoms and underlying genetic causes. Treatment aims to reduce seizure frequency and control myoclonus, improving the quality of life for those affected.
Repurposable Drugs: There are no established repurposable drugs specifically for the treatment of Progressive Myoclonus Epilepsy (PME). Treatment typically focuses on managing symptoms using anticonvulsants like valproic acid, levetiracetam, or clonazepam, but these are not considered repurposable specifically for PME.
Metabolites: In the context of progressive myoclonus epilepsy (PME), specific metabolites may vary depending on the underlying genetic cause. Typically, PME can be associated with abnormal accumulation or deficiency of certain metabolites. For example, in Lafora disease (a type of PME), there is an accumulation of abnormal glycogen. In other types, such as certain lipid storage disorders, there may be an accumulation of lipids. Detailed metabolic profiling usually helps in diagnosing and differentiating various forms of PME.
Nutraceuticals: Nutraceuticals are food-derived products that offer health and medical benefits, including the prevention and treatment of disease. Currently, there is limited scientific evidence to specifically support the use of nutraceuticals for treating or managing Progressive Myoclonus Epilepsy (PME). Management of PME typically focuses on antiepileptic medications to control seizures, as well as supportive therapies to address neurological symptoms. Nutraceuticals may play a complementary role in overall health but are not a primary treatment option for PME. Always consult a healthcare provider before starting any new supplement regimen.
Peptides: Progressive Myoclonus Epilepsy (PME) refers to a group of rare genetic disorders characterized by myoclonus (involuntary muscle jerks), seizures, and progressive neurological decline. Peptides in the context of PME are being studied for their potential therapeutic effects, as they may help modify the disease process or alleviate symptoms. Nanotechnology (commonly abbreviated as "nan") is also being explored in PME for its potential in delivering targeted treatments and improving drug delivery systems at the molecular level, which could enhance the efficacy and reduce side effects of therapies.